Results for active comparator translation from English to Danish

active comparator
aktiv komparator

48-week active comparator controlled study
48-ugers aktiv komparator-kontrolleret studie

active comparator trials (n=2569) evaluable patients
studie med aktiv komparator (n=2569) evaluerbare patienter

this is similar to that seen in a sulphonylurea active comparator group.
lignende blev observeret i den sammenlignende aktive gruppe, der fik sulfonylurinstof.

in study i, superiority of tocilizumab 8 mg/kg was demonstrated against the active comparator mtx.
i studie i var tocilizumab 8 mg/kg bedre end den aktive komparator mtx.

study 2 contained the active comparator, leuprorelin 3.75 mg given once per month by intramuscular injection.
studie 2 indeholdt den aktive komparator, leuprorelin 3,75 mg, der blev givet én gang dagligt som intramuskulær injektion.

in active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2 ­ 3 kg over one year.
i kontrollerede kliniske forsøg med aktive stoffer som sammenligning var den gennemsnitlige vægtøgning 2-3 kg i løbet af et år ved pioglitazon givet som monoterapi.

32 in active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2 – 3 kg over one year.
i kontrollerede kliniske forsøg med aktive stoffer som sammenligning var den gennemsnitlige vægtøgning 2- 3 kg i løbet af et år ved pioglitazon givet som monoterapi.

with an efficacy of 98-100% in serum testosterone reduction further active comparator studies are redundant and thus not necessary.
med en virkning på 98- 100% i reduktion af serum- testosteron er yderligere undersøgelser med aktivt sammenligningspræparat overflødige.

in active comparator-controlled trials, mean weight increase with pioglitazone given as monotherapy was 2-3 kg over one year.
i aktivt kontrollerede komparator-studier af pioglitazon givet som enkeltstofbehandling var den gennemsnitlige vægtforøgelse 2 - 3 kg i løbet af et år.

in study 1, 122 patients were treated with opicapone 5 mg and 122 patients were treated with entacapone 200 mg (active comparator).
i studie 1 blev 122 patienter behandlet med opicapon 5 mg, og 122 patienter blev behandlet med entacapon 200 mg (aktiv komparator).

the pivotal controlled studies involved 6,089 patients receiving humira and 3,801 patients receiving placebo or active comparator during the controlled period.
de pivotale kontrollerede studier, som omfattede 6.089 patienter, der fik humira, og 3.801 patienter, der fik enten placebo eller aktiv kontrol i den kontrollerede behandlingsperiode.

the safety and efficacy of lemtrada were evaluated in 3 randomised, rater-blinded, active-comparator clinical trials in patients with rrms.
lemtradas sikkerhed og virkning blev evalueret i 3 randomiserede, rater-blindede, aktiv-komperator kliniske forsøg med rrms-patienter.

in the other three studies, which did include an active comparator, there were no differences in scores between the patients taking thymanax and those taking placebo.
i de andre tre undersøgelser med et aktivt sammenligningsstof var der ingen forskel i resultaterne mellem patienter, som tog thymanax, og dem, der tog placebo.

clinical efficacy was demonstrated in two placebo-controlled studies and one active-comparator study in 448 patients randomised to receive quinsair 240 mg twice daily.
klinisk virkning er blevet vist i to placebokontrollerede studier og ét aktiv komparator-studie med 448 patienter randomiseret til at få quinsair 240 mg to gange dagligt.

anoro showed a statistically significant reduction in sgrq total score compared with tiotropium in one of the three active-comparator studies (see table 1).
anoro viste statistisk signifikant reduktion af samlet sgrq-score sammenlignet med tiotropium i et af de tre studier med aktiv komparator (se tabel 1).

in a clinical trial with liraglutide as monotherapy, rates of hypoglycaemia reported with liraglutide were lower than rates reported for patients treated with active comparator (glimepiride).
i ét klinisk studie med liraglutid som monoterapi, var de rapporterede hypoglykæmirater for liraglutid lavere end de rapporterede rater for patienter, der blev behandlet med en aktiv komparator (glimepirid).

in active-comparator studies with either valsartan or ramipril, the blood-pressure-lowering effect with edarbi was sustained during long-term treatment.
i studier med aktive komparatorer med enten valsartan eller ramipril blev edarbis antihypertensive virkning opretholdt ved langtidsbehandling.

in seven double blind controlled studies, a total of 5,941 patients (3,672 given edarbi, 801 given placebo, and 1,468 given active comparator) were evaluated.
i syv dobbeltblinde, kontrollerede studier blev i alt 5941 patienter vurderet (3672 fik edarbi, 801 fik placebo og 1468 fik en aktiv komparator).

results of the confirmatory phase iii study the efficacy and safety of degarelix was evaluated in an open-label, multi-centre, randomised, active comparator controlled, parallel-group study.
effekt og sikkerhed af degarelix blev evalueret i et åbent, multi- center, randomiseret, aktiv komparator kontrolleret, parallel- gruppe forsøg.